Zobrazeno 1 - 10
of 11 943
pro vyhledávání: '"Poly (ADP- ribose) polymerase inhibitors"'
Autor:
Zheng Q; School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, No.1166 Liutai Avenue, Wenjiang District, Chengdu, Sichuan, 611137, China.; Department of Oncology, Hospital of Chengdu Uiversity of Traditional Chinese Medicine, Chengdu, Sichuan, 610075, China., Zhou T; Department of Oncology, Sichuan Integrative Medicine Hospital, Chengdu, Sichuan, 610042, China., Ding W; School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, No.1166 Liutai Avenue, Wenjiang District, Chengdu, Sichuan, 611137, China. dingweijun@cdutcm.edu.cn.
Publikováno v:
Clinical & experimental metastasis [Clin Exp Metastasis] 2024 Dec; Vol. 41 (6), pp. 843-850. Date of Electronic Publication: 2024 Sep 04.
Autor:
Kawai-Kawachi A; The ATIP-Avenir Inserm and ERC StG (Epi)genetic Vulnerabilities in Solid Tumors and Sarcoma Laboratory, Inserm Unit UMR 981, Université Paris-Saclay, Gustave Roussy, Villejuif, France.; Cancer RNA Research Unit, National Cancer Center Research Institute, Tokyo, Japan., Lenormand MM; The ATIP-Avenir Inserm and ERC StG (Epi)genetic Vulnerabilities in Solid Tumors and Sarcoma Laboratory, Inserm Unit UMR 981, Université Paris-Saclay, Gustave Roussy, Villejuif, France.; Department of Genomes and Genetics, Institut Pasteur, CNRS UMR3525, Paris, France., Astier C; The ATIP-Avenir Inserm and ERC StG (Epi)genetic Vulnerabilities in Solid Tumors and Sarcoma Laboratory, Inserm Unit UMR 981, Université Paris-Saclay, Gustave Roussy, Villejuif, France.; Université Paris-Saclay, Université Paris-Sud XI, Faculté de Médicine, Le Kremlin Bicêtre, France., Herbel N; The ATIP-Avenir Inserm and ERC StG (Epi)genetic Vulnerabilities in Solid Tumors and Sarcoma Laboratory, Inserm Unit UMR 981, Université Paris-Saclay, Gustave Roussy, Villejuif, France.; Université Paris-Saclay, Université Paris-Sud XI, Faculté de Médicine, Le Kremlin Bicêtre, France.; Drug Development Department, DITEP, Gustave Roussy, Villejuif, France.; Sarcoma Committee, Gustave Roussy, Villejuif, France.; Viroxis SAS Biotech, Gustave Roussy, Villejuif, France., Cutrona MB; Organoid Core Facility, Gustave Roussy, Villejuif, France., Ngo C; The ATIP-Avenir Inserm and ERC StG (Epi)genetic Vulnerabilities in Solid Tumors and Sarcoma Laboratory, Inserm Unit UMR 981, Université Paris-Saclay, Gustave Roussy, Villejuif, France.; Sarcoma Committee, Gustave Roussy, Villejuif, France., Garrido M; The ATIP-Avenir Inserm and ERC StG (Epi)genetic Vulnerabilities in Solid Tumors and Sarcoma Laboratory, Inserm Unit UMR 981, Université Paris-Saclay, Gustave Roussy, Villejuif, France., Eychenne T; The ATIP-Avenir Inserm and ERC StG (Epi)genetic Vulnerabilities in Solid Tumors and Sarcoma Laboratory, Inserm Unit UMR 981, Université Paris-Saclay, Gustave Roussy, Villejuif, France., Dorvault N; The ATIP-Avenir Inserm and ERC StG (Epi)genetic Vulnerabilities in Solid Tumors and Sarcoma Laboratory, Inserm Unit UMR 981, Université Paris-Saclay, Gustave Roussy, Villejuif, France., Bordelet L; Experimental and Translational Pathology (PETRA) Platform, AMMICa Unit (CNRS Unit UMS 3655, Inserm Unit US 23), Gustave Roussy, Villejuif, France., Song F; The CRUK Gene Function Laboratory and Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom., Bouyakoub R; Organoid Core Facility, Gustave Roussy, Villejuif, France., Loktev A; Sarcoma Molecular Pathology Team, Divisions of Molecular Pathology and Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Romo-Morales A; Sarcoma Molecular Pathology Team, Divisions of Molecular Pathology and Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Henon C; The ATIP-Avenir Inserm and ERC StG (Epi)genetic Vulnerabilities in Solid Tumors and Sarcoma Laboratory, Inserm Unit UMR 981, Université Paris-Saclay, Gustave Roussy, Villejuif, France.; Drug Development Department, DITEP, Gustave Roussy, Villejuif, France.; Sarcoma Committee, Gustave Roussy, Villejuif, France., Colmet-Daage L; The ATIP-Avenir Inserm and ERC StG (Epi)genetic Vulnerabilities in Solid Tumors and Sarcoma Laboratory, Inserm Unit UMR 981, Université Paris-Saclay, Gustave Roussy, Villejuif, France., Vibert J; The ATIP-Avenir Inserm and ERC StG (Epi)genetic Vulnerabilities in Solid Tumors and Sarcoma Laboratory, Inserm Unit UMR 981, Université Paris-Saclay, Gustave Roussy, Villejuif, France.; Drug Development Department, DITEP, Gustave Roussy, Villejuif, France.; Sarcoma Committee, Gustave Roussy, Villejuif, France., Drac M; Institute of Molecular Genetics, CNRS Unit UMR 5535, Université de Montpellier, Montpellier, France., Brough R; The CRUK Gene Function Laboratory and Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom., Schwob E; Institute of Molecular Genetics, CNRS Unit UMR 5535, Université de Montpellier, Montpellier, France., Martella O; Organoid Core Facility, Gustave Roussy, Villejuif, France., Pinna G; RNA Interference Platform PARi, IRCM/IBFJ/CEA UMRE008, Fontenay-aux-Roses, France., Shipley JM; Sarcoma Molecular Pathology Team, Divisions of Molecular Pathology and Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Mittnacht S; UCL Cancer Institute, University College London, London, United Kingdom., Zimmermann A; Research Unit Oncology, The Healthcare Business of Merck KGaA, Darmstadt, Germany., Gulati A; The CRUK Gene Function Laboratory and Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom., Mir O; Sarcoma Committee, Gustave Roussy, Villejuif, France., Le Cesne A; Sarcoma Committee, Gustave Roussy, Villejuif, France., Faron M; Sarcoma Committee, Gustave Roussy, Villejuif, France., Honoré C; Sarcoma Committee, Gustave Roussy, Villejuif, France., Lord CJ; The CRUK Gene Function Laboratory and Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom., Chabanon RM; The ATIP-Avenir Inserm and ERC StG (Epi)genetic Vulnerabilities in Solid Tumors and Sarcoma Laboratory, Inserm Unit UMR 981, Université Paris-Saclay, Gustave Roussy, Villejuif, France.; Université Paris-Saclay, Université Paris-Sud XI, Faculté de Médicine, Le Kremlin Bicêtre, France.; The CRUK Gene Function Laboratory and Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom., Postel-Vinay S; The ATIP-Avenir Inserm and ERC StG (Epi)genetic Vulnerabilities in Solid Tumors and Sarcoma Laboratory, Inserm Unit UMR 981, Université Paris-Saclay, Gustave Roussy, Villejuif, France.; Université Paris-Saclay, Université Paris-Sud XI, Faculté de Médicine, Le Kremlin Bicêtre, France.; Drug Development Department, DITEP, Gustave Roussy, Villejuif, France.; Sarcoma Committee, Gustave Roussy, Villejuif, France.; UCL Cancer Institute, University College London, London, United Kingdom.
Publikováno v:
Cancer research [Cancer Res] 2025 Jan 02; Vol. 85 (1), pp. 154-170.
Autor:
Kam CMT; Medicinal Chemistry Group, Faculty of Health Sciences and Medicine, Bond University, Robina, Queensland, Australia., Tauber AL; Medicinal Chemistry Group, Faculty of Health Sciences and Medicine, Bond University, Robina, Queensland, Australia., Zunk MS; School of Pharmacy and Medical Sciences, Griffith University, Southport, Queensland, Australia., McDermott CM; Centre for Urology Research, Faculty of Health Sciences and Medicine, Bond University, Robina, Queensland, Australia., Levonis SM; Medicinal Chemistry Group, Faculty of Health Sciences and Medicine, Bond University, Robina, Queensland, Australia., Schweiker SS; Medicinal Chemistry Group, Faculty of Health Sciences and Medicine, Bond University, Robina, Queensland, Australia.
Publikováno v:
Future medicinal chemistry [Future Med Chem] 2025 Jan; Vol. 17 (1), pp. 35-58. Date of Electronic Publication: 2024 Dec 18.
Autor:
Bai YR; Department of Pharmacy, Children's Hospital Affiliated to Zhengzhou University, Henan Children's Hospital, Zhengzhou Children's Hospital, Zhengzhou, China.; Key Laboratory of Advanced Drug Preparation Technologies, School of Pharmacy, Zhengzhou University, Zhengzhou, China., Yang WG; Department of Pharmacy, Children's Hospital Affiliated to Zhengzhou University, Henan Children's Hospital, Zhengzhou Children's Hospital, Zhengzhou, China., Jia R; Department of Pharmacy, Children's Hospital Affiliated to Zhengzhou University, Henan Children's Hospital, Zhengzhou Children's Hospital, Zhengzhou, China., Sun JS; Department of Pharmacy, Children's Hospital Affiliated to Zhengzhou University, Henan Children's Hospital, Zhengzhou Children's Hospital, Zhengzhou, China., Shen DD; Department of Obstetrics and Gynecology, Zhengzhou Key Laboratory of Endometrial Disease Prevention and Treatment, Zhengzhou, China.; Gynecology Department, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China., Liu HM; Department of Pharmacy, Children's Hospital Affiliated to Zhengzhou University, Henan Children's Hospital, Zhengzhou Children's Hospital, Zhengzhou, China.; Key Laboratory of Advanced Drug Preparation Technologies, School of Pharmacy, Zhengzhou University, Zhengzhou, China., Yuan S; Department of Pharmacy, Children's Hospital Affiliated to Zhengzhou University, Henan Children's Hospital, Zhengzhou Children's Hospital, Zhengzhou, China.; Key Laboratory of Advanced Drug Preparation Technologies, School of Pharmacy, Zhengzhou University, Zhengzhou, China.
Publikováno v:
Medicinal research reviews [Med Res Rev] 2025 Jan; Vol. 45 (1), pp. 214-273. Date of Electronic Publication: 2024 Aug 24.
Autor:
Johannes JW; Chemistry, Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Balazs AYS; Chemistry, Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Barratt D; Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Bista M; Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Chuba MD; Chemistry, Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Cosulich S; Oncology Projects, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Critchlow SE; Bioscience, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Degorce SL; Chemistry, Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Di Fruscia P; Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Edmondson SD; Chemistry, Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Embrey KJ; New Modalities & Parenteral Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, U.K., Fawell S; Oncology Discovery, Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Ghosh A; Chemistry, Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Gill SJ; Safety Sciences, Clinical Pharmacology and Safety Sciences R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Gunnarsson A; Discovery Sciences, R&D Gothenburg, AstraZeneca, Pepparedsleden 1, SE-431 83 Mölndal, Sweden., Hande SM; Chemistry, Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Heightman TD; Chemistry, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Hemsley P; Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Illuzzi G; Bioscience, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Lane J; Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Larner CJB; Safety Sciences, Clinical Pharmacology and Safety Sciences R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Leo E; Bioscience, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Liu L; Pharmaron Beijing Co., Ltd., 6 Taihe Road, BDA, Beijing 100176, P. R. China., Madin A; Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., McWilliams L; Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., O'Connor MJ; Bioscience, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Orme JP; Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Pachl F; Discovery Sciences, R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Packer MJ; Computational Chemistry, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Pei X; Pharmaron Beijing Co., Ltd., 6 Taihe Road, BDA, Beijing 100176, P. R. China., Pike A; DMPK, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Schimpl M; Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., She H; Pharmaron Beijing Co., Ltd., 6 Taihe Road, BDA, Beijing 100176, P. R. China., Staniszewska AD; Bioscience, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Talbot V; Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Underwood E; Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Varnes JG; Chemistry, Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Xue L; Pharmaron Beijing Co., Ltd., 6 Taihe Road, BDA, Beijing 100176, P. R. China., Yao T; Pharmaron Beijing Co., Ltd., 6 Taihe Road, BDA, Beijing 100176, P. R. China., Zhang K; Pharmaron Beijing Co., Ltd., 6 Taihe Road, BDA, Beijing 100176, P. R. China., Zhang AX; Discovery Sciences, R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Zheng X; Chemistry, Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.
Publikováno v:
Journal of medicinal chemistry [J Med Chem] 2024 Dec 26; Vol. 67 (24), pp. 21717-21728. Date of Electronic Publication: 2024 Dec 10.
Autor:
Pham TD; Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. thao.pham@northwestern.edu.; The Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA. thao.pham@northwestern.edu., Becker JH; Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.; Jesse Brown VA Medical Center, Chicago, IL, USA., Metropulos AE; Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.; Jesse Brown VA Medical Center, Chicago, IL, USA., Mubin N; Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.; Jesse Brown VA Medical Center, Chicago, IL, USA., Spaulding C; Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA., Bentrem DJ; Jesse Brown VA Medical Center, Chicago, IL, USA.; The Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA.; Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA., Munshi HG; Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. h-munshi@northwestern.edu.; Jesse Brown VA Medical Center, Chicago, IL, USA. h-munshi@northwestern.edu.; The Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA. h-munshi@northwestern.edu.
Publikováno v:
BMC cancer [BMC Cancer] 2024 Dec 20; Vol. 24 (1), pp. 1562. Date of Electronic Publication: 2024 Dec 20.
Autor:
Rajawat J; Institute of Advanced Molecular Genetics & Infectious Diseases, ONGC-CAS, University of Lucknow, Lucknow, 226007, U.P, India; Molecular & Human Genetics Lab, Department of Zoology, University of Lucknow, Lucknow, 226007, U.P, India. Electronic address: jrajawat@gmail.com., Banerjee M; Molecular & Human Genetics Lab, Department of Zoology, University of Lucknow, Lucknow, 226007, U.P, India; A Laboratory of Advanced Molecular Genetics & Infectious Diseases, ONGC-CAS, University of Lucknow, Lucknow, 226007, U.P, India. Electronic address: monishabanerjee30@gmail.com.
Publikováno v:
Biochemical and biophysical research communications [Biochem Biophys Res Commun] 2024 Dec 17; Vol. 738, pp. 150943. Date of Electronic Publication: 2024 Nov 02.
Autor:
Gao S; Discovery & Early Development, Haihe Biopharma Co., Ltd, Shanghai 201203, China., Hou Y; Discovery & Early Development, Haihe Biopharma Co., Ltd, Shanghai 201203, China., Xu Y; Discovery & Early Development, Haihe Biopharma Co., Ltd, Shanghai 201203, China., Li J; Discovery & Early Development, Haihe Biopharma Co., Ltd, Shanghai 201203, China., Zhang C; Discovery & Early Development, Haihe Biopharma Co., Ltd, Shanghai 201203, China., Jiang S; Discovery & Early Development, Haihe Biopharma Co., Ltd, Shanghai 201203, China., Yu S; Discovery & Early Development, Haihe Biopharma Co., Ltd, Shanghai 201203, China., Liu L; Discovery & Early Development, Haihe Biopharma Co., Ltd, Shanghai 201203, China., Li L; Discovery & Early Development, Haihe Biopharma Co., Ltd, Shanghai 201203, China., Tu W; Discovery & Early Development, Haihe Biopharma Co., Ltd, Shanghai 201203, China., Yu B; Discovery & Early Development, Haihe Biopharma Co., Ltd, Shanghai 201203, China., Zhang Y; Discovery & Early Development, Haihe Biopharma Co., Ltd, Shanghai 201203, China.
Publikováno v:
Journal of medicinal chemistry [J Med Chem] 2024 Dec 12; Vol. 67 (23), pp. 21380-21399. Date of Electronic Publication: 2024 Nov 21.
Autor:
Seed G; The Institute of Cancer Research, London, UK., Beije N; The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK., Yuan W; The Institute of Cancer Research, London, UK., Bertan C; The Institute of Cancer Research, London, UK., Goodall J; The Institute of Cancer Research, London, UK., Lundberg A; The Institute of Cancer Research, London, UK., Tyler M; The Institute of Cancer Research, London, UK., Figueiredo I; The Institute of Cancer Research, London, UK., Pereira R; The Institute of Cancer Research, London, UK., Baker C; The Institute of Cancer Research, London, UK., Bogdan D; The Institute of Cancer Research, London, UK., Gallagher L; The Institute of Cancer Research, London, UK., Cieslik JP; Heinrich Heine University, Düsseldorf, Germany., Greening S; The Institute of Cancer Research, London, UK., Lambros M; The Institute of Cancer Research, London, UK., Neves R; Heinrich Heine University, Düsseldorf, Germany., Magraner-Pardo L; The Institute of Cancer Research, London, UK., Fowler G; The Institute of Cancer Research, London, UK., Ebbs B; The Institute of Cancer Research, London, UK., Miranda S; The Institute of Cancer Research, London, UK., Flohr P; The Institute of Cancer Research, London, UK., Bianchini D; The Royal Marsden NHS Foundation Trust, London, UK., Rescigno P; The Institute of Cancer Research, London, UK., Porta N; The Institute of Cancer Research, London, UK., Hall E; The Institute of Cancer Research, London, UK., Gurel B; The Institute of Cancer Research, London, UK., Tunariu N; The Royal Marsden NHS Foundation Trust, London, UK., Sharp A; The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK., Pettit S; The Institute of Cancer Research, London, UK., Stoecklein NH; Heinrich Heine University, Düsseldorf, Germany., Sandhu S; The Royal Marsden NHS Foundation Trust, London, UK., Quigley D; UCSF, San Francisco, CA, USA., Lord CJ; The Institute of Cancer Research, London, UK., Mateo J; Vall d'Hebron Institute of Oncology, Barcelona, Spain., Carreira S; The Institute of Cancer Research, London, UK., de Bono J; The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK. Electronic address: johann.de-bono@icr.ac.uk.
Publikováno v:
Cancer cell [Cancer Cell] 2024 Dec 09; Vol. 42 (12), pp. 2113-2123.e4. Date of Electronic Publication: 2024 Nov 21.
Autor:
Malik U; Department of Pharmacy, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur, C.G., 495009, India., Pal D; Department of Pharmacy, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur, C.G., 495009, India. Electronic address: drdilip2003@yahoo.co.in.
Publikováno v:
European journal of medicinal chemistry [Eur J Med Chem] 2024 Dec 05; Vol. 279, pp. 116898. Date of Electronic Publication: 2024 Sep 24.